EScitalopram PIndolol ONset of Action

Unipolar Depression Clinical Trial

— ESPION  

Official title:

Antidepressant Effect of Escitalopram: Delay of Onset. Clinical Randomized Double-blinded Study With Three Parallel Treatment Groups (Escitalopram 20mg vs Escitalopram 30mg vs Escitalopram 20 mg + Pindolol 15 mg/Day

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01219686
• Other study ID #: CER 09-054, Psy 09-004
• Status: Terminated
• Phase: Phase 2/Phase 3
• First received: October 7, 2010
• Last updated: May 26, 2015
• Start date: October 2010
• Est. completion date: June 2013

Study information

• Verified date: May 2015
• Source: University Hospital, Geneva
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to determine whether the antidepressant response of escitalopram 30mg/day or escitalopram 20mg/day + pindolol, a beta blocker, is different (faster) compared to a standard dose of escitalopram 20mg/day.

Description:

Antidepressant drug therapy is the primary therapeutic treatment option in moderate to severe Major Depressive Disorder. However, clinically significant antidepressant response needs sustained treatment during weeks to months. Indeed, in the largest effectiveness study conducted to date (STAR*D study) involving nearly 3000 depressed outpatients, only about one third of those who ultimately responded did so after 6 weeks of drug treatment and for most patients longer treatment periods were necessary. This delay implies prolonged suffering for the patients and their families. By its antagonist action on the serotonin 1A receptor pindolol is hypothesized to reduce the down-regulation mechanisms of antidepressants. It is therefore expected that addition of pindolol to escitalopram will shorten the therapeutic response. Clinical and preclinical data indicate that escitalopram at 30 mg/day might be more effective and perhaps be associated with a faster onset of action than 20mg. For this purpose the speed of action will be compared between three blindly randomized samples:

• escitalopram 20mg per day + placebo

• escitalopram 30mg per day + placebo

• escitalopram 20mg per day + pindolol 15mg per day (two doses of 7.5mg during 14 days).

Subjects will be followed for 6 weeks. The dose of 15mg pindolol per day (during 14 days) is based on the optimal occupancy of the serotonin 1A receptor.

At inclusion all subjects will be assessed by a trained psychiatrist using the SCID I mood disorder part which is based on DSM IV criteria, and by means of the French version of the MINI. Severity of depression will be assessed using the MADRS clinician rated and self-report questionnaire, and the French version of the QIDS.

Each week subjects will be assessed using the two versions of the Montgomery-Asberg Depression Rating Scale (MADRS) and the HCL-32 a self-report questionnaire assessing hypomania.

It is planned to include 135 patients during the three years of the study duration resulting in 45 subjects in each group.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: June 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• patients aged between 18 and 65 years old

• patients suffering from major depression according to DSM-IV with a MADRS score of at least 25 and not treated by an antidepressant at the time of inclusion with the exception of non-responders to antidepressant for a period of at least 6 weeks or not tolerating an ongoing antidepressant necessitating a change of the antidepressant(excluding fluoxetine and irreversible MAOI)

• informed consent

Exclusion criteria:

• any other Axis I disorder excluding anxiety disorder not dominating the clinical picture, nicotine abuse

• non-responders to escitalopram in the past

• already taking pindolol

• pregnancy and breast feeding

• contraindication to one of the two treatments (medical conditions, drug treatments)

• significant somatic comorbidity interfering with the study procedures

• high risk of suicidality

• women of childbearing age not having a safe means of contraception

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depressive Disorder
• Unipolar Depression

Intervention

Drug:
• escitalopram, pindolol
escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
• escitalopram
escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
• escitalopram
escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg

Locations

Country	Name	City	State
Switzerland	Centre de Thérapies Breves (CTB), Secteur Jonction	Geneva

Sponsors (5)

Lead Sponsor	Collaborator
Markus KOSEL	H. Lundbeck A/S, University Hospital, Basel, Switzerland, University Hospital, Geneva, University of Lausanne Hospitals

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MADRS score change between baseline and 2 weeks of treatment	Differences in MADRS score changes (baseline-day 14) between treatment groups	day 14	No
Secondary	Response/remission (MADRS) at 6 weeks	% of patients with a given treatment which meet response/remssion criteria after 6 weeks of treatment, based on MADRS	day 42	No
Secondary	Adverse events	Frequence of adverse events in treatment groups	See primary outcome measure	Yes
Secondary	Correlation of drug level of pindolol and/or escitalopram and clinical outcome (primary outcome) between treatment groups		Day 10	No